Chaudhuri A (2013) Multiple sclerosis is primarily a neurodegenerative disease. J Neural Transm (Vienna) 120:1463–1466. https://doi.org/10.1007/s00702-013-1080-3

Article  CAS  PubMed  Google Scholar 

Tillery EE, Clements JN, Howard Z (2017) What’s new in multiple sclerosis? Ment Health Clin 7(5):213–220

Article  PubMed  Google Scholar 

Adamczyk B, Adamczyk-Sowa M (2016) New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. https://doi.org/10.1155/2016/1973834

Article  PubMed  PubMed Central  Google Scholar 

Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. https://doi.org/10.1155/2013/708659

Article  PubMed  PubMed Central  Google Scholar 

Sallusto F (2016) Heterogeneity of human CD4+ T cells against microbes. Annu Rev Immunol 34:317–334. https://doi.org/10.1146/annurev-immunol-032414-112056

Article  CAS  PubMed  Google Scholar 

Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F (2014) T helper cells plasticity in inflammation. Cytometry A 85(1):36–42. https://doi.org/10.1002/cyto.a.22348

Article  CAS  PubMed  Google Scholar 

Kolls JK, Lindén A (2004) Interleukin-17 family members and inflammation. Immunity 21(4):467–476. https://doi.org/10.1016/j.immuni.2004.08.018

Article  CAS  PubMed  Google Scholar 

Wing AC, Hygino J, Ferreira TB, Kasahara TM, Barros PO, Sacramento PM, Andrade RM, CamargoS RF, Alves-Leon SV, Vasconcelos CC, Alvarenga R, Bento CA (2016) Interleukin-17-and interleukin-22-secreting myelin-specific CD 4+ T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients. Immunology 147(2):212–220. https://doi.org/10.1111/imm.12552

Article  CAS  PubMed  Google Scholar 

Kuntzel T, Bagnard D (2022) Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis. Pharmaceutics 14(2):344. https://doi.org/10.3390/pharmaceutics14020344

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mao P, Reddy PH (2010) Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta Mol Basis Dis 1802(1):66–79

Article  CAS  Google Scholar 

Largani SHH, Borhani-Haghighi M, Pasbakhsh P, Mahabadi VP, Nekoonam S, Shiri E, Kashani IR, Zendehdel A (2019) Oligoprotective effect of metformin through the AMPK-dependent on restoration of mitochondrial hemostasis in the cuprizone-induced multiple sclerosis model. J Mol Histol 50:263–271. https://doi.org/10.1007/s10735-019-09824-0

Article  CAS  PubMed  Google Scholar 

Addabbo F, Montagnani M, Goligorsky MS (2009) Mitochondria and reactive oxygen species. Hypertension 53(6):885–892

Article  CAS  PubMed  Google Scholar 

Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264(12):2351–2374. https://doi.org/10.1007/s00415-017-8594-9

Article  PubMed  PubMed Central  Google Scholar 

Filipi M, Jack S (2020) Interferons in the treatment of multiple Sclerosis: A clinical efficacy, safety, and tolerability update. Int J MS Care 22(4):165–172. https://doi.org/10.7224/1537-2073.2018-063

Article  PubMed  Google Scholar 

Li H, Hu F, Zhang Y, Li K (2020) Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol 267(12):3489–3498. https://doi.org/10.1007/s00415-019-09395-w

Article  PubMed  Google Scholar 

Sattarnezhad N, Healy BC, Baharnoori M, Diaz-Cruz C, Stankiewicz J, Weiner HL, Chitnis T (2022) Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. BMC Neurol 22(1):252. https://doi.org/10.1186/s12883-022-02761-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N’Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH (2022) Effect of dimethyl fumarate vs interferon β-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial. JAMA Netw Open 5(9):e2230439. https://doi.org/10.1001/jamanetworkopen.2022.30439

Article  PubMed  PubMed Central  Google Scholar 

Ning P, Luo A, Mu X, Xu Y, Li T (2022) Exploring the dual character of metformin in Alzheimer’s disease. Neuropharmacology 207:108966. https://doi.org/10.1016/j.neuropharm.2022.108966

Article  CAS  PubMed  Google Scholar 

Feng YY, Wang Z, Pang H (2023) Role of metformin in inflammation. Mol Biol Rep 50(1):789–798. https://doi.org/10.1007/s11033-022-07954-5

Article  CAS  PubMed  Google Scholar 

Buczyńska A, Sidorkiewicz I, Krętowski AJ, Zbucka-Krętowska M, Adamska A (2022) Metformin intervention—a panacea for cancer treatment? Cancers 14(5):1336

Article  PubMed  PubMed Central  Google Scholar 

Khezri MR, Yousefi K, Mahboubi N, Hodaei D, Ghasemnejad-Berenji M (2022) Metformin in Alzheimer’s disease: An overview of potential mechanisms, preclinical and clinical findings. Biochem Pharmacol 197:114945. https://doi.org/10.1016/j.bcp.2022.114945

Article  CAS  PubMed  Google Scholar 

Tawfik TZ, Gad AH, Mehaney DA, El Nahrery EE, Shehata HS, Hashem H, Abdel Ghaffar NF, Shalaby N (2016) Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients. J Neurol Sci 369:36–38. https://doi.org/10.1016/j.jns.2016.07.034

Article  CAS  PubMed  Google Scholar 

van der Vuurst de Vries RM, Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP, de Beukelaar JWK, Wokke BHA, Siepman TAM, Hintzen RQ (2018) Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol 75(11): 1392-1398. 1001/jamaneurol.2018.2160

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444

Article  CAS  PubMed  Google Scholar 

Cunniffe N (2021) Promoting and measuring remyelination and neuroprotection in clinical trials of people with multiple sclerosis. Dissertation, University of Cambridge. https://doi.org/10.17863/CAM.77136

Ovcharova E, Danovska M, Marinova D, Pendicheva-Duhlenska D, Tonchev P, Atanasova M, Ruseva A, Shepherd N, Tzveova R (2022) Adapted Mediterranean Diet Impact on the Symptoms of Chronic Fatigue, Serum Levels of Omega-3 Polyunsaturated Fatty Acids (PUFAs) and Interleukin 17 (IL-17) in Patients with Relapsing-Remitting Multiple Sclerosis undergoing Disease-Modifying Therapy: A Pilot Study. J IMAB 28(1):4297–4304. https://doi.org/10.5272/jimab.2022281.4297

Article  Google Scholar 

Noroozi S, Arababadi MK, Meimand HAE, Asadikaram G (2017) The effect of IFN-β 1a on biochemical factors in multiple sclerosis patients. Iran Red Crescent Med J 19(8):e41032

Google Scholar 

Green AE (2013) AMP-activated protein kinase (AMPK) activation for the treatment of mitochondrial disease. Dissertation, York University.

Hagen J, Zimmerman R, Goetz C, Bonnevier J, Houchins JP, Reagan K, Kalyuzhny AE (2015) Comparative multi-donor study of IFNγ secretion and expression by human PBMCs using ELISPOT side-by-side with ELISA and flow cytometry assays. Cells 4(1):84–95

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji N, Forsthuber TG (2016) ELISPOT techniques. Methods Mol Biol 1304:63–71. https://doi.org/10.1007/7651_2014_111

Article  PubMed  Google Scholar 

Abdel-Dayem MA, Shaker ME, Gameil NM (2019) Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 337:577062. https://doi.org/10.1016/j.jneuroim.2019.577062

Article  CAS  PubMed  Google Scholar 

Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, Tilea B, Tiu C (2017) Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. CNS Neurol Disord Drug Targets 16(1):93–101. https://doi.org/10.2174/1871527315666160615110739

Article  CAS  PubMed  Google Scholar 

Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M (2015) Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. J Neuroimmunol 285:125–128. https://doi.org/10.1016/j.jneuroim.2015.05.022

Article  CAS  PubMed  Google Scholar 

Bălaşa R, Bajko Z, Huţanu A (2013) Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β. Mult Scler 19(7):885–890. https://doi.org/10.1177/1352458512468497

Article  CAS  PubMed  Google Scholar 

Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, Barrett-Connor E, Randolph JF (2012) Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab 97(11):4051–4060

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonnet F, Scheen A (2017) Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 19(4):473–481. https://doi.org/10.1111/dom.12854

Article